Evidence map›Paper›PMID 28969077›Full record

ArticleOncotarget2017

Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis.

Susu Han, Wei Yang, Shaoqi Zong, Hongjia Li, Shanshan Liu, Wen Li, Qi Shi, Fenggang Hou

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.Journal of experimental & clinical cancer research : CR · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Multifaceted Interpretation of Colon Cancer Stem Cells.International journal of molecular sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Susu HanOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Wei YangOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Shaoqi ZongOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Hongjia LiOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Shanshan LiuOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Wen LiOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Qi ShiOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Fenggang HouOncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai TCM University, Shanghai, People's Republic of China.
Shanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD166 has been identified as an important cancer stem cell (CSC) marker in colorectal cancer (CRC). The purpose of our study was to investigate the relationship between CD166 expression and clinical features and to examine the role of CD166 expression on the survival of patients with CRC. A total of 15 studies with 3,332 cases were identified in this meta-analysis. The pooled OR indicated that CD166 expression was significantly higher in CRC than in colonic adenomas or normal colonic mucosa (OR = 3.48,

Indexed as

CD166clinical featuresCRCexpressionsurvival

Identifiers

PMID28969077
PMCPMC5610009
OpenAlexW2608958493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.